Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb™-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose

Journal article published in 2022 by C. Michael Gibson, Michael J. Mack, Victoria T. Lee, David J. Schneider , Frank W. Sellke , E. Magnus Ohman, Vinod H. Thourani, Gheorghe Doros, Hans Kroger, Donald E. Cutlip , Efthymios N. Deliargyris

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by